Overview

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Status:
Withdrawn

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label trial to evaluate the safety of continued therapy with subcutaneous Remodulin® in subjects with pulmonary arterial hypertension (PAH) who complete the CVT-CV-003 study. The study will include about 50 subjects at up to 10 clinical trial centers in China who completed all required assessments in the CVT-CV-003 study. Study visits for data collection will occur at month 6 and 12 with yearly visits beyond 12 months until the study is discontinued by the sponsor.

Phase:

Phase 4

Details

Lead Sponsor:

United Therapeutics

Collaborator:

CVie Therapeutics Co. Ltd.

Treatments:

Treprostinil